MPN Research Foundation Presents Key Research on Myeloproliferative Neoplasms at ASH 2025 The MPN Research Foundation is set to present two crucial research abstracts on myeloproliferative neoplasms at ASH 2025, focusing on patient and caregiver needs.

MPN Research Foundation Presents Key Research on Myeloproliferative Neoplasms at ASH 2025 #USA #Orlando #Myeloproliferative_Neoplasms #Polycythemia_Vera #MPN_Research_Foundation

Vanda Pharmaceuticals Secures Orphan Drug Status for Innovative Polycythemia Vera Treatment VGT-1849B Vanda Pharmaceuticals has announced that the FDA has granted Orphan Drug Designation to their new treatment, VGT-1849B, targeting polycythemia vera.

Vanda Pharmaceuticals Secures Orphan Drug Status for Innovative Polycythemia Vera Treatment VGT-1849B #United_States #Washington #Vanda_Pharmaceuticals #Polycythemia_Vera #VGT-1849B

The Evolving Landscape of Polycythemia Vera Treatment Marked by Competitive Pharma Developments Amidst increasing competition, the polycythemia vera treatment market is expanding with emerging therapies and innovative solutions to manage this rare disorder effectively.

The Evolving Landscape of Polycythemia Vera Treatment Marked by Competitive Pharma Developments #United_States #Las_Vegas #Polycythemia_Vera #JAKAFI #BESREMi